Hypercalcemia-induced renal insufficiency during therapy with dihydrotachysterol.
During vitamin-D therapy drug accumulation and intoxication should be considered. In the present study we report on five patients with renal insufficiency during therapy with dihydrotachysterol or calcitriol. Four patients received dihydrotachysterol for 29 (7-44) years and one patient received calcitriol for 4 years to treat hypoparathyroidism after thyroid surgery. As confirmed by renal biopsy impairment of renal function was due to calcifications as a consequence of prolonged hypercalcemia. The effective duration of dihydrotachysterol is ten days as compared with five days for calcitriol. Severe hypercalcemic episodes with dihydrotachysterol are longer-lasting than those with the shorter acting vitamin-D derivatives. Further, they occur with higher incidence as was shown by our own observations and previously published data by other workers. Hence, impairment of renal function during therapy with dihydrotachysterol should be considered as being due to hypercalcemia and hypercalciuria.
Jehle
D R
DR
Department of Internal Medicine II, University of Ulm, Germany.
Keller
F
F
Schwarz
A
A
Jehle
P M
PM
D000368:Aged; D002117:Calcitriol / Q000009:adverse effects / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D004097:Dihydrotachysterol / Q000009:adverse effects* / Q000627:therapeutic use; D062787:Drug Overdose; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced*; D007668:Kidney / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000139:chemically induced*; D014463:Ultrasonography
D003404:Creatinine; D002117:Calcitriol; D004097:Dihydrotachysterol; D002118:Calcium